UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (State or other jurisdiction of incorporation or organization) Delaware 84 ...

Core Viewpoint - PMGC Capital LLC urges Alaunos Therapeutics, Inc. to accept a financing term sheet that could provide substantial capital and create significant shareholder value [1][4]. Group 1: PMGC Capital's Position - PMGC Capital holds a significant ownership position in Alaunos and is acting in the best interest of all shareholders [2]. - The proposed financing, introduced by PMGC Capital and led by a leading Wall Street bank, is described as a compelling opportunity for Alaunos [3]. - PMGC Capital emphasizes the importance of engaging with the bank to maximize long-term value for shareholders [4]. Group 2: Financing Details - The financing offer is characterized as non-toxic and well-structured, providing substantial capital to Alaunos [4]. - PMGC Capital commends Alaunos for maintaining a clean capital structure and prudent financial management during challenging market conditions [5]. Group 3: Company Background - PMGC Capital is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies across diverse markets [6]. - PMGC Holdings Inc. manages a diversified portfolio through strategic acquisitions and investments across various industries [7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Commission ...

Financial Performance - For the year ended December 31, 2024, the company reported a net loss of $4.6 million, with an accumulated deficit of approximately $920.4 million since its inception in 2003[348]. - Revenue for the year ended December 31, 2024, was $10 thousand, a 100% increase from $5 thousand in 2023[364]. - The company has not generated any product revenue and continues to incur significant operating expenditures and net losses[348]. - As of December 31, 2024, the accumulated deficit was approximately $920.4 million, indicating ongoing financial challenges[381]. - Cash and cash equivalents as of December 31, 2024 were approximately $1.1 million, with expectations to fund operations into the second quarter of 2025[384]. - No collaboration revenue was earned in 2024, with only $10 thousand in royalty revenues compared to $5 thousand in 2023 under the Solasia License[387]. Expenses - Research and development expenses decreased by 98% to $362 thousand in 2024 from $16.3 million in 2023, primarily due to reduced clinical activities and workforce[365]. - General and administrative expenses decreased by 63% to $4.46 million in 2024 from $12.22 million in 2023, mainly due to a reduction in consulting and employee-related expenses[367]. - Impairments for the year ended December 31, 2024 were $0 million, a decrease of 100% from $4.8 million in 2023, following a strategic reprioritization announced in August 2023[371]. - Net cash used in operating activities for 2024 was $5.0 million, significantly reduced from $30.1 million in 2023, attributed to a net loss of $4.6 million and adjustments for non-cash items[378]. Strategic Initiatives - The company is exploring strategic alternatives, including acquisitions, mergers, and partnerships, to extend its cash runway[347]. - The company has engaged Cantor Fitzgerald & Co. as a strategic advisor to assist in exploring strategic alternatives[347]. - Management has raised substantial doubt about the company's ability to continue as a going concern beyond the forecasted cash runway[377]. Clinical Trials and Studies - The ongoing in vitro study aims to evaluate the impact of ALN1001 on lipid metabolism, with results expected in early Q2 2025[350]. - The TCR-T Library Phase 1/2 Trial showed a 13% overall response rate and an 87% disease control rate among evaluable patients[352]. - The company plans to conduct a proof-of-concept study for its obesity program by Q3 2025, contingent on successful in vitro study results[351]. Licensing and Agreements - The company terminated a Patent License agreement effective December 26, 2023, incurring no expenses under this agreement in 2024, compared to $0.3 million in 2023[386].

Financial Performance - For the six months ended June 30, 2024, the company reported a net loss of $3.2 million, with an accumulated deficit of approximately $918.9 million since inception in 2003[39]. - Revenue for the three months ended June 30, 2024, was $4 thousand, unchanged from the same period in 2023, while revenue for the six months ended June 30, 2024, increased by 50% to $6 thousand compared to $4 thousand in 2023[46]. - The company has not generated any product revenue and continues to incur significant operating expenditures and net losses for the foreseeable future[39]. - Other income (expense), net, for the three months ended June 30, 2024, increased by $0.8 million compared to the same period in 2023, primarily due to no interest expense associated with the former amended Loan and Security Agreement[51]. - For the six months ended June 30, 2024, other income (expense), net, increased by $1.3 million compared to the same period in 2023, again primarily due to no interest expense associated with the former amended Loan and Security Agreement[52]. - The company recorded revenue of $5 thousand and $6 thousand under the License and Collaboration Agreement for the three and six months ended June 30, 2024, respectively[57]. Expenses and Cost Management - Research and development expenses for the three months ended June 30, 2024, decreased by 97% to $180 thousand from $5.2 million in the same period in 2023, primarily due to the wind-down of clinical activities[47]. - General and administrative expenses for the three months ended June 30, 2024, decreased by 67% to $990 thousand from $3.0 million in the same period in 2023, attributed to reduced headcount[49]. - Net cash used in operating activities for the six months ended June 30, 2024, was $3.6 million, a decrease from $16.4 million for the same period in 2023, primarily due to changes in net loss[54]. Strategic Initiatives - The company has engaged Cantor Fitzgerald & Co. as a strategic advisor to explore alternatives including acquisitions, mergers, and capital raises[39]. - The company is exploring strategic alternatives, including acquisitions, mergers, and capital raises, while engaging Cantor as a strategic advisor[53]. - The company has reduced its workforce by approximately 95% to extend its cash runway amid strategic reprioritization[42]. Compliance and Financial Position - The company received a delisting determination from Nasdaq due to its stock price falling below $0.10 per share, but has since regained compliance with the minimum bid price requirement[43]. - As of June 30, 2024, the accumulated deficit was approximately $918.9 million, with cash and cash equivalents of approximately $2.5 million[55]. - Working capital as of June 30, 2024, was $3.4 million, down from $6.3 million as of December 31, 2023[55]. - The company anticipates that cash resources will be sufficient to fund operations into the third quarter of 2024, but additional financing will be necessary to continue operations beyond that point[55]. Research and Development Updates - The TCR-T Library Phase 1/2 Trial treated eight patients, achieving a total overall response rate of 13% and a disease control rate of 87% in evaluable patients[40]. - The company announced the termination of its Cooperative Research and Development Agreement with the National Cancer Institute effective October 13, 2023[39]. - No royalty payments were recognized under the Patent License for the three and six months ended June 30, 2024, while $0.3 million was recognized in the same periods of 2023[56].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-33038 Alaunos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 84-1475642 (State or Other Jurisdiction of In ...

Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delawa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 84 ...

Financial Data and Key Metrics Changes - For Q1 2023, the company reported a net loss of approximately $10 million, or a $0.04 net loss per share, compared to a net loss of approximately $9.8 million, or a $0.05 net loss per share for the same period in 2022, indicating a slight increase in losses [22] - Research and development expenses increased by 17% to approximately $6.5 million in Q1 2023 from approximately $5.6 million in Q1 2022, primarily due to increased manufacturing and TCR discovery activities [23] - General and administrative expenses decreased by 10% to approximately $3.2 million in Q1 2023 from approximately $3.5 million in Q1 2022, attributed to lower professional fees [24] - As of March 31, 2023, total cash balances were approximately $37.4 million, with an operating cash burn of approximately $9.4 million for Q1 2023, up from approximately $7.8 million in Q1 2022 [25][27] Business Line Data and Key Metrics Changes - The company is focused on advancing its TCR platform targeting solid tumors, with significant enhancements made to screening enrollment and manufacturing processes, facilitating faster patient accrual [3][4] - The TCR library Phase 1/2 trial is actively enrolling patients across six solid tumor indications, with expectations to treat between nine and twelve patients by the end of the year [5][6] Market Data and Key Metrics Changes - The company noted that investor engagement remains encouraging, with evidence pointing to supportive capital markets for companies with differentiated science [28] - The follow-on market has raised $7.3 billion by 60 follow-ons year-to-date, compared to $4.6 billion raised in 44 follow-ons at the same point in 2022, indicating a positive trend for biotech [36] Company Strategy and Development Direction - The company aims to become a Phase 2-ready company by the end of 2023, with recent corporate and capital changes supporting the belief in the upside potential of its TCR platform [1][6] - The amendment of the license agreement with Precigen eliminates all commercial sales-based royalties and milestone obligations, representing potential savings of over $160 million [7][9] - The company is expanding its TCR library through the Hunter platform, targeting more HLAs and new mutations to bolster its IP portfolio and pipeline [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their TCR-T platform to transform cancer treatment, highlighting early clinical responses and accelerated patient enrollment [33][35] - The management team is optimistic about the upcoming interim results in Q3, which are expected to provide a more comprehensive readout of clinical data [5][39] Other Important Information - The company fully prepaid its term loan with Silicon Valley Bank, allowing for complete operational control over cash and eliminating additional interest expenses [9][27] - The company has implemented cryopreservation in its manufacturing process, increasing flexibility for patient scheduling and treatment [3][4] Q&A Session Summary Question: Update on ASCO data presentation - Management confirmed that the poster will include data on the first three patients treated, but further details cannot be disclosed until the embargo lifts on May 25 [50] Question: Change in target enrollment for Phase 1 - Management clarified that the guidance remains unchanged, with the nine to twelve patients expected to complete Phase 1 including those treated in 2022 [55] Question: Confidence in interim update financing - Management expressed confidence that the cash runway will extend to the next data readout, while remaining opportunistic regarding fundraising options [56][57] Question: Interim readout patient dosing levels - Management indicated that multiple patients will be included in the clinical update in Q3, with flexibility in trial design regarding dosing levels [60] Question: Manufacturing capacity for Phase 2 - Management discussed a multipronged manufacturing strategy to increase capacity for Phase 2, utilizing both in-house and external resources [62][64] Question: Cash balance clarification - Management confirmed that the $13.9 million of restricted cash is included in the total cash balance of $37.4 million as of March 31, 2023 [80]